Requires gene synthesis providers and manufacturers of gene synthesis equipment to operate in accordance with rules and regulations issued by the department of health, including identifying potentially dangerous sequences and maintaining certain records.
Impact
The implementation of Bill S09279 will significantly amend the public health law, specifically by introducing a new article that sets forth stringent operational criteria for gene synthesis labs. By establishing these regulations, the bill addresses the potential risks associated with synthetic biology and bioengineering, particularly in the context of bioterrorism. The health department will adopt generally accepted industry standards, thereby aligning state regulations with national and international guidelines, which can elevate safety protocols across the state.
Summary
Bill S09279, referred to as the 'Bioterrorism Prevention Act', introduces new regulations pertaining to gene synthesis providers and manufacturers of gene synthesis equipment in the State of New York. The bill mandates these entities to operate according to rules established by the Department of Health, focusing on identifying potentially dangerous genetic sequences and maintaining accurate records of synthesized genes. This legislation seeks to bolster public health safety by ensuring oversight and compliance within the growing field of genetic technology.
Contention
Although the bill has clear intentions of enhancing public safety, there may be concerns regarding its impact on innovation and research within the gene synthesis sector. Some stakeholders may argue that over-regulation could stifle advancements in biotechnology and hinder the growth of businesses operating in this field. Additionally, the requirement for thorough record-keeping and screening procedures may raise operational costs for companies, potentially leading to a pushback from industry representatives who argue for more balanced regulatory approaches.
Same As
Requires gene synthesis providers and manufacturers of gene synthesis equipment to operate in accordance with rules and regulations issued by the department of health, including identifying potentially dangerous sequences and maintaining certain records.
Requires gene synthesis providers and manufacturers of gene synthesis equipment to operate in accordance with rules and regulations issued by the department of health, including identifying potentially dangerous sequences and maintaining certain records.
Requires the department of health to enter into a contract with an entity experienced in maintaining genealogical research databases for the digitalization and indexing of certain vital records.
Requires the department of health to enter into a contract with an entity experienced in maintaining genealogical research databases for the digitalization and indexing of certain vital records.
Requires the department of health to enter into a contract with an entity experienced in maintaining genealogical research databases for the digitalization and indexing of certain vital records.
A BILL to amend the Code of Virginia by adding sections numbered 32.1-127.1:06 and 38.2-3407.15:9, relating to genetic sequencing; organ transplants; use of foreign genetic sequencing or genetic sequencer operational and research software; foreign storage of genetic sequencing data; health insurance coverage for certain foreign organ transplants; civil penalty.
Limits the reimbursement amount of certain overpayment claims and reviews where such overpayment was due to the provider's submission of records which were not in accordance with program requirements at the time but which were in accordance with current requirements as a result of changes to guidelines or regulations.
Limits the reimbursement amount of certain overpayment claims and reviews where such overpayment was due to the provider's submission of records which were not in accordance with program requirements at the time but which were in accordance with current requirements as a result of changes to guidelines or regulations.
Requires the owner or operator of a new data center to submit to the Public Service Commission a thermal energy network feasibility assessment that identifies potential off-site thermal loads within one mile of the facility; requires that new data centers be designed, constructed, and operated to capture and reuse waste heat generated by computing equipment through a thermal energy network.
Enacts the manufacturer disclosure and transparency act requiring prescription drug manufacturers to notify the attorney general of arrangements between pharmaceutical manufacturers resulting in the delay of the introduction of generic medications.